A5076877188- Diabetes Treatment and Management
- Diabetes Management and Research
- Metabolism, Diabetes, and Cancer
- Pancreatic function and diabetes
- Pharmacology and Obesity Treatment
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Thyroid Cancer Diagnosis and Treatment
- Diabetes and associated disorders
- Neuroendocrine Tumor Research Advances
- Adrenal Hormones and Disorders
- Pituitary Gland Disorders and Treatments
- Urticaria and Related Conditions
- Parathyroid Disorders and Treatments
- Thyroid Disorders and Treatments
- Hormonal Regulation and Hypertension
- Acne and Rosacea Treatments and Effects
- Herpesvirus Infections and Treatments
- Diet and metabolism studies
- Adrenal and Paraganglionic Tumors
- Autoimmune Bullous Skin Diseases
- Skin Diseases and Diabetes
- Cytomegalovirus and herpesvirus research
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Peroxisome Proliferator-Activated Receptors
- Diabetes Management and Education
Faculdade de Medicina de Jundiaí
2024-2025
Thomas Jefferson University
2015-2024
Thomas Jefferson University Hospital
2000-2024
Centre Hospitalier de l’Université de Montréal
2024
Triangle
2020
Jefferson College
2007-2018
University of Tennessee at Knoxville
2018
Jefferson University Hospitals
2017
Office of Naval Research
2017
Diabetes Australia
2009-2010
Glucagon-like peptide-1 (GLP-1) receptor agonists are effective therapies for the treatment of type 2 diabetes and all currently available as an injection.To compare effects oral semaglutide with placebo (primary) open-label subcutaneous (secondary) on glycemic control in patients diabetes.Phase 2, randomized, parallel-group, dosage-finding, 26-week trial 5-week follow-up at 100 sites (hospital clinics, general practices, clinical research centers) 14 countries conducted between December...
To assess the efficacy and safety of dapagliflozin as add-on therapy in patients with type 2 diabetes who were inadequately controlled a dipeptidyl peptidase-4 inhibitor or without metformin.In this 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 study 24-week blinded extension period, 432 randomized to receive 10 mg/day placebo added sitagliptin (100 mg/day) ± metformin (≥1,500 mg/day).Baseline HbA1c FPG levels 7.9% (63.0 mmol/mol) 162.2 mg/dL...
OBJECTIVE This 24-week, double-blinded, phase 3 clinical trial (DEPICT-2; ClinicalTrials.gov, NCT02460978) evaluated efficacy and safety of dapagliflozin as adjunct therapy to adjustable insulin in patients with inadequately controlled type 1 diabetes (HbA1c 7.5–10.5%). RESEARCH DESIGN AND METHODS Patients were randomized 1:1:1 5 mg (n = 271), 10 270), or placebo 272) plus insulin. Insulin dose was adjusted by investigators according self-monitored glucose readings, local guidance,...
To assess whether the secular trends in type 2 diabetes prevalence differ between abdominally obese and non-obese individuals.Data from National Health Nutrition Examination Surveys (NHANES) were used to estimate of abdominal obesity among individuals aged ≥20 years USA 1999/2000 2013/2014, after standardization age, sex ethnicity population distribution estimates on January 1, 2014, as published by US Census Bureau.The increased 47.4% (95% confidence interval [CI] 42.6-52.2) 57.2% CI...
OBJECTIVE Among patients with type 2 diabetes uncontrolled metformin, exenatide once weekly (QW) plus dapagliflozin combination produced greater reductions in glycemia, weight, and systolic blood pressure (SBP) at 28 weeks than QW or alone (DURATION-8). Here, we investigated the safety maintenance of efficacy 52 weeks, after a 24-week extension. RESEARCH DESIGN AND METHODS This phase 3, multicenter, double-blind study randomized adults (with glycated hemoglobin [HbA1c] 8.0–12.0% [64–108...
Metformin, a biguanide antihyperglycemic medication, lowers blood glucose in patients with type 2 diabetes minimal risk of hypoglycemia. Most common side effects include diarrhea, nausea and vomiting. Extended-release metformin (Glucophage XR)*, once-daily tablet using the patented GelShield Diffusion System release mechanism, may be better tolerated than immediate-release (Glucophage). This retrospective chart review examined overall gastrointestinal (GI) tolerability both...
Background: Although the medical community acknowledges importance of preoperative glycemic control, literature is inconclusive and proper metric for assessment control remains unclear. Serum fructosamine reflects mean in a shorter time period compared with glycated hemoglobin (HbA1c). Our aim was to examine its role predicting adverse outcomes following total joint arthroplasty. Methods: Between 2012 2013, we screened all patients undergoing arthroplasty preoperatively using serum HbA1c,...
Abstract Aim To assess the efficacy of exenatide (EXE) once weekly + dapagliflozin daily (DAPA) versus each drug alone in reducing biomarkers fatty liver/steatosis and fibrosis a post hoc analysis DURATION‐8, 104‐week study 695 patients with type 2 diabetes uncontrolled by metformin monotherapy. Materials methods We evaluated impact treatments on non‐invasive markers hepatic steatosis (fatty liver index [FLI] non‐alcoholic disease [NAFLD] fat score), (fibrosis‐4 [FIB‐4]) severe (NAFLD along...
To compare the efficacy and safety of adding glucagon-like peptide-1 receptor agonist exenatide once weekly (QW) 2 mg or placebo among patients with type diabetes who were inadequately controlled despite titrated insulin glargine (IG) ± metformin.This multicentre, double-blind study (ClinicalTrials.gov identifier: NCT02229383) randomized (1:1) persistent hyperglycaemia after an 8-week titration phase (glycated haemoglobin [HbA1c] 7.0%-10.5% [53-91 mmol/mol]) to QW placebo. The primary...
To determine the incidence and manifestations of hypoglycemia in hospitalized patients receiving antihyperglycemic therapy.The study was a 3-month prospective review consecutive medical records all adult, nonpregnant at 675-bed university hospital who experienced least 1 blood glucose (BG) <or= 60 mg/dL within 48 hours an agent.Of 2174 agents, 206 (9.5%) 484 hypoglycemic episodes. Of these episodes, 29% occurred with type diabetes, 23% ICU, 72% only insulin for hyperglycemia. More than...
Aims To compare the safety and efficacy of a simpler titration algorithm for insulin degludec/liraglutide ( IDegLira ) with that used in previous DUAL trials insulin‐naïve patients type 2 diabetes. Research design methods This 32‐week, open‐label, non‐inferiority trial randomized adults diabetes uncontrolled on metformin ± pioglitazone to receive , titrated either once weekly, based mean pre‐breakfast plasma glucose PG readings (n = 210), or twice 3 210). Results Mean HbA1c decreased from...
In patients with type 2 diabetes uncontrolled metformin, exenatide once weekly (QW) plus dapagliflozin produced greater reductions in glycemic parameters (glycated hemoglobin [HbA1c], fasting plasma glucose [FPG], and 2-h postprandial [2-h PPG]), weight, systolic blood pressure (SBP) than QW or alone after 28 weeks of treatment DURATION-8. Following a 24-week extension period, improvements were sustained at 52 weeks. this study, we investigated efficacy safety 104 randomization.DURATION-8...
Abstract 6‐Nitrodopamine (6‐ND) is the main catecholamine released from human isolated vas deferens and adrenergic nervous system known to play a major role in contractions of epididymal portion deferens. Here it was investigated interactions 6‐ND on induced by either classical catecholamines or electric‐field stimulation (EFS). The obtained 106 patients who underwent vasectomy surgery were mounted 10‐mL glass chamber filled with warmed (37°C) oxygenated Krebs–Henseleit's solution. strips...